Cencora, Inc. (NYSE:COR) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 31.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,106 shares of the company's stock after purchasing an additional 7,171 shares during the quarter. Daiwa Securities Group Inc.'s holdings in Cencora were worth $6,764,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Swedbank AB increased its stake in Cencora by 2.3% during the third quarter. Swedbank AB now owns 1,394,449 shares of the company's stock worth $313,863,000 after purchasing an additional 31,104 shares during the period. CWA Asset Management Group LLC acquired a new position in shares of Cencora in the third quarter valued at approximately $285,000. United Bank increased its stake in Cencora by 4.2% during the 3rd quarter. United Bank now owns 5,601 shares of the company's stock worth $1,261,000 after buying an additional 225 shares during the period. Assetmark Inc. lifted its holdings in Cencora by 33.8% during the 3rd quarter. Assetmark Inc. now owns 2,536 shares of the company's stock worth $571,000 after buying an additional 641 shares in the last quarter. Finally, Axxcess Wealth Management LLC boosted its position in Cencora by 9.5% in the 3rd quarter. Axxcess Wealth Management LLC now owns 10,389 shares of the company's stock valued at $2,338,000 after buying an additional 901 shares during the period. Institutional investors and hedge funds own 97.52% of the company's stock.

Insider Transactions at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the sale, the chief accounting officer now owns 20,154 shares of the company's stock, valued at $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,648 shares of company stock valued at $3,382,462 over the last quarter. Company insiders own 10.80% of the company's stock.

Cencora Trading Down 0.3 %

NYSE COR opened at $260.87 on Wednesday. The company has a 50-day moving average of $245.81 and a 200-day moving average of $238.70. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $263.70. The company has a market cap of $50.59 billion, a P/E ratio of 37.11, a P/E/G ratio of 1.31 and a beta of 0.51.

Remove Ads

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.

Analysts Set New Price Targets

Several research analysts recently commented on the company. JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Evercore ISI upped their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Mizuho initiated coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 target price on the stock. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday. Finally, Wells Fargo & Company raised their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.